Epidemiological Characteristics of Gastric and Pancreatic Cancers in Latin America

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-11

Study Completion Date

2024-09-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Currently, there is no Brazilian or Latin American epidemiological data, such as clinical-pathological characteristics, standard treatments and outcomes of gastric cancer and pancreatic cancer in the region. The study aims to create a Latin American multicenter database to analyze epidemiological, clinical, and pathological data, treatments, outcomes, and biological information from patients with gastric and pancreatic cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer

NCT05356039

Pancreas Cancer Pancreas Neoplasm Pancreas Disease +6 more

RECRUITING

Pancreatic Adenocarcinoma Gene Environment Risk Study

NCT00912717

Pancreatic Cancer

RECRUITING

Multi-omics Characterization of Pancreatic Neuroendocrine Tumors and Carcinomas

NCT05234450

Cancer of Pancreas

UNKNOWN

Gene Expression in Pancreatic Cancer

NCT03531125

Pancreatic Cancer

TERMINATED

The Role of Systemic Immuno-inflammatory Factors in Resectable Pancreatic Adenocarcinoma

NCT05025371

Pancreas Cancer, Duct Cell Adenocarcinoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients diagnosed with gastric and gastroesophageal junction or pancreatic cancer after January 2019 at participating sites will be included. Data will be collected from medical records in selected centers that comprise different countries from Latin America. Data collection will begin on the time of site activation.

Patients recruited for this study will be identified in the participating sites. Data from clinical, demographic, and socioeconomic variables will be collected. Also, data on treatments performed and outcomes will be abstracted. The patient data sources will be the medical records of the patients. Patients will continue to receive treatment and clinical evaluations for gastric and gastroesophageal junction or pancreatic cancer according to what is determined by their medical team, according to the usual standards of treatment and clinical practice of each center.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer GastroEsophageal Cancer Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort A

120 patients with histological diagnosis of gastric and gastroesophageal junction cancer.

Observational study

Intervention Type OTHER

This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Cohort B

80 patients histological diagnosis of pancreatic cancer.

Observational study

Intervention Type OTHER

This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational study

This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥18 years
* Histological diagnosis of gastric and gastroesophageal junction cancer (Cohort A) or histological diagnosis of pancreatic cancer (Cohort B);
* Advanced disease diagnosis from January 2019: patients can be included prospectively. Advanced disease is defined as metastatic disease or locally advanced disease not amenable to curative therapy;
* Availability of adequate medical data for data collection.

Exclusion Criteria

* Synchronous invasive tumor or second primary tumor in the last three years (except thyroid tumors or non-melanoma skin);
* Nonepithelial histology in Cohort A: Sarcoma, GIST, lymphoma, and tumors of neuroendocrine origin;
* Nonepithelial histology in Cohort B: Sarcoma, GIST, lymphoma, pancreatoblastoma, and tumors of neuroendocrine origin.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No